(MedPage Today) — The FDA approved doxecitine and doxribtimine powder (Kygevvi) for thymidine kinase 2 deficiency (TK2d), an ultra-rare mitochondrial depletion syndrome, the agency announced on Monday.
A pair of pyrimidine nucleosides, the doxecitine…
Source link : https://www.medpagetoday.com/genetics/generalgenetics/118289
Author :
Publish date : 2025-11-03 20:06:00
Copyright for syndicated content belongs to the linked Source.
